A bipartisan coalition of 41 state attorneys general, led by Connecticut Attorney General William Tong, is urging Congress to swiftly pass the Combating Illicit Xylazine Act. The proposed legislation aims to address the growing threat of xylazine, a powerful animal tranquilizer increasingly found mixed with illicit opioids like fentanyl, and contributing to a surge in overdose deaths across the country. The attorneys general argue that classifying xylazine as a Schedule I controlled substance is a critical step toward curbing its spread and providing law enforcement with the tools they need to combat the crisis.
The escalating presence of xylazine in the illicit drug supply presents a unique challenge to public health and safety. Unlike opioids, xylazine does not respond to naloxone, the life-saving medication used to reverse opioid overdoses. In other words that even when administered, naloxone may not be effective in cases where xylazine is present, significantly increasing the risk of fatal outcomes. The Drug Enforcement Administration (DEA) has identified xylazine as an emerging drug threat, noting a dramatic increase in its involvement in overdose deaths nationwide. According to the DEA, the amount of xylazine seized by law enforcement has increased by over 500% since 2020.
“Illicit xylazine is costing lives in Connecticut and across the country,” Attorney General Tong stated in a press release. “It’s being mixed with opioids, driving deadly overdoses, and making this crisis even harder to fight. Congress must act now to make xylazine a controlled substance and give law enforcement the tools to stop its spread and save lives.” The coalition’s letter to House and Senate leadership details the dangers of the drug and the necessity of federal intervention.
What is Xylazine and Why is it So Dangerous?
Xylazine, often referred to as “tranq,” is a veterinary sedative primarily used for large animals like horses and livestock. It’s approved for veterinary use only and is not intended for human consumption. The drug works by depressing the central nervous system, causing drowsiness, reduced heart rate, and slowed breathing. When combined with opioids, particularly fentanyl, xylazine significantly amplifies the risk of respiratory depression and overdose. The DEA warns that even a small amount of xylazine can cause severe health consequences, including tissue damage, coma, and death.
The increasing prevalence of xylazine is particularly concerning because of its effects on the body. Beyond the lack of response to naloxone, xylazine can cause severe skin ulcerations and soft tissue infections, often requiring amputation. These wounds are slow to heal and are prone to secondary infections, further complicating treatment. The combination of these factors is overwhelming healthcare systems and straining resources dedicated to addressing the opioid crisis.
The Combating Illicit Xylazine Act: What Would it Do?
The proposed legislation, the Combating Illicit Xylazine Act, seeks to address the xylazine crisis through a multi-pronged approach. Primarily, it would classify xylazine as a Schedule I controlled substance under the Controlled Substances Act. This would give the DEA the authority to track the manufacturing, distribution, and diversion of the drug, and impose stricter penalties for those involved in its illegal trafficking.
The Act also mandates the establishment of a national reporting system to collect data on xylazine-related overdoses and deaths. This data would be used to better understand the scope of the problem and inform public health interventions. The legislation calls for increased collaboration between federal, state, and local law enforcement agencies to disrupt the supply chain of xylazine and target those responsible for its distribution. The Senate Judiciary Committee advanced the legislation with bipartisan support last week, signaling a growing recognition of the urgency of the issue.
A Bipartisan Effort to Combat a Growing Crisis
The coalition of attorneys general leading the charge on this issue represents a broad spectrum of political ideologies and geographic locations. Co-leading the effort alongside Attorney General Tong are the attorneys general of New York, Arkansas, and Tennessee. The group includes officials from 41 states, the District of Columbia, American Samoa, and the U.S. Virgin Islands, demonstrating the widespread concern over the impact of xylazine.
The attorneys general argue that the lack of federal oversight has allowed xylazine to proliferate in the illicit drug market, and that a coordinated national response is essential to effectively address the problem. They emphasize that the crisis is not confined to any one region, and that all states are vulnerable to the dangers of xylazine. The coalition’s unified voice underscores the bipartisan commitment to finding solutions to the opioid epidemic and protecting public health.
What’s Next?
With the Senate Judiciary Committee having already advanced the Combating Illicit Xylazine Act, the next step is a vote by the full Senate. Following Senate approval, the bill would then be sent to the House of Representatives for consideration. The attorneys general are urging Congress to prioritize this legislation and pass it without delay. They believe that swift action is crucial to prevent further loss of life and mitigate the devastating consequences of xylazine contamination in the illicit drug supply.
The ongoing opioid crisis continues to evolve, presenting new and complex challenges. The emergence of xylazine as a significant threat underscores the need for continued vigilance, innovation, and collaboration in addressing this public health emergency. The attorneys general remain committed to working with federal and state partners to implement effective strategies to combat the opioid epidemic and protect communities across the country.
If you or someone you grasp is struggling with substance use disorder, please reach out for facilitate. You can contact the Substance Abuse and Mental Health Services Administration (SAMHSA) National Helpline at 1-800-662-HELP (4357) or visit their website at https://www.samhsa.gov/.
What are your thoughts on the proposed legislation? Share your comments below and help us continue the conversation.
